A Phase 1b Dose Escalation, Open-label Study Of CP-751,871 In Combination With Docetaxel In Advanced Non-hematologic Malignancies
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Advanced Non-Hematologic Malignancies
Both
Advanced Non-Hematologic Malignancies
Trial Information
A Phase 1b Dose Escalation, Open-label Study Of CP-751,871 In Combination With Docetaxel In Advanced Non-hematologic Malignancies
Inclusion Criteria:
- Age greater than 18 years
- Documented advanced-stage non-hematologic malignancy for whom docetaxel monotherapy
is a reasonable treatment option
- Eastern Cooperative Oncology Group [ECOG] performance status 0-1
Exclusion Criteria:
- Significant active cardiac disease
- Chemotherapy, biological or investigational agents within 4 weeks prior to dosing
- Inadequate bone marrow, renal, cardiac or liver function
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Maximum tolerated dose
Outcome Time Frame:
Cycle 1 Day 1 through Cycle 1 Day 21
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A4021003
NCT ID:
NCT01653158
Start Date:
March 2005
Completion Date:
February 2009
Related Keywords:
- Advanced Non-hematologic Malignancies
- non-hematologic cancer
- advanced solid tumors
- prostrate cancer
- Neoplasms
Name | Location |
|---|
